1 Use of cfDNA and exovesicle-DNA for the molecular diagnosis of chronic Chagas

- 2 disease.
- 3 Noelia Lozano^{1, 2}; Mercedes Gomez Samblas ³*, Eva Calabuig⁴, María José Giménez
- 4 Martí², Maria Dolores Gómez Ruiz², José Miguel Sahuquillo Arce², José Miguel Molina
- 5 Moreno², M. Trelis ^{1, 5} y Antonio Osuna³*
- 6 1.- Area of Parasitology. Department of Pharmacy and Pharmaceutical Technology and
- 7 Parasitology. University of Valencia. 46010 Valencia, Spain.
- 8 2.- Servicio de Microbiología y Parasitología Clínica. Hospital Universitario y Politécnico
- 9 La Fe-IIS La Fe, 46010 Valencia, Spain.
- 10 3.- Grupo de Bioquímica y Parasitología Molecular (CTS 183), Departamento de
- Parasitología, Campus de Fuentenueva, Instituto de Biotecnología, Universidad deGranada, 18071 Granada, Spain.
- 4.- Unidad de Enfermedades Infecciosas. Servicio de Medicina Interna. Hospital
 Universitario y Politécnico La Fe-IIS La Fe. Valencia 46010, Spain.
- 5.- Joint Research Unit on Endocrinology. Nutrition and Clinical Dietetics, University of
 Valencia-Health Research Institute La Fe, Valencia 46010, Spain.
- * Authors for correspondence: Antonio Osuna. Email: <u>aosuna@ugr.es</u> and Mercedes
 Gomez-Samblas. Email: <u>msambla@ugr.es</u>
- 19
- key words: *Trypanosoma cruzi*, chronic Chagas disease, PCR diagnosis, plasma
 exovesicles, cfDNA.
- 22

23 Abstract

Chagas disease is, among others, considered a neglected tropical disease. Given the magnitude of the human movements that have occurred in recent years from Central and South America to other countries, Chagas should now be considered a disease of worldwide distribution, in which the transmission of the parasite is restricted to transplacental transmission or blood or organ donations from infected people.

Parasite detection in chronically ill patients is restricted to serological tests that only
 determine previous contact and not the presence of the parasite, especially in those
 patients undergoing treatment evaluation or in newborns.

In this study, we evaluate the use of nucleic acids from both circulating serum exovesicles and cell-free DNA (cfDNA) from 448 serum samples from immunologically diagnosed chronic chagasic patients, which were re-evaluated by nested PCR on the amplicons resulting from amplification with kDNA-specific primers 121F-122R. Of the total number of samples selected, 50 were used to isolate and purify exovesicles from circulating serum and cell-free DNA (cfDNA).

When the nucleic acids thus purified were assayed as a template and amplified with primers 121F-122R and SAT, a percentage positivity of 100% was obtained for all positive samples assayed with the kDNA-specific primers and 96% when SAT primers were used. However, isolation of cfDNA for *T. cruzi* and amplification with SAT primers also showed 100% positivity. Hence, both samples can be used in those cases where it is necessary to demonstrate the active presence of the parasite.

44 INTRODUCTION

45 *Trypanosoma cruzi* is a flagellated protozoan etiologically responsible for American 46 trypanosomiasis or Chagas Disease (CD); a disease considered a zoonosis within the

so-called neglected tropical diseases. In addition to humans, CD involves wild or 47 domestic mammals. Hematophagous insects belonging to the Triatominae family 48 (Reduviid) are responsible for CD transmission, acting as invertebrate hosts or vectors. 49 The protozoa multiply in the vector's midgut as epimastigote forms and finally reach the 50 end of the intestine and rectal ampulla giving rise to the infective form or metacyclic 51 trypomastigotes. With insect defecation after biting, these infective forms are deposited 52 53 on the skin and they will access the mammalian host through the wound or through mucous membranes invading the nucleated cells. Then, they can multiply as amastigote 54 forms. Parasites differentiate into trypomastigotes, which disrupt the host cell, invade 55 56 intercellular spaces and penetrate neighboring cells or enter the bloodstream, 57 disseminating the infection through the blood. Blood trypomastigote forms will wait to be ingested by a new vector. Non-vectorial human infection can occur by oral, transfusional 58 (1,2), or vertical routes from mother to fetus (3). These last two routes are of 59 epidemiological importance in areas without vectorial transmission. 60

Chagas disease is endemic in a total of 21 countries in the Americas, from the southern 61 62 United States to Argentina and Chile (4,5), with about 10 million people infected, and an annual incidence of 50,000 to 200,000 infections (5). The disease, considered for many 63 64 years to be restricted to Meso- and South America, has spread to other parts of the world due to migratory processes. Human-to-human cases have been described in the 65 United States, Canada, European countries, Australia or Japan, areas with varying 66 67 degrees of migration from endemic areas (6), turning Chagas into a public health problem in European countries such as Spain, Italy or Sweden, among others, where 68 strict control measures have thus been taken in blood banks (7), gynecological services 69 (8) and transplant surgeries (9–11). 70

71 The course of the disease has two marked phases: acute and chronic. Acute Chagas 72 disease (ACD) occurs within the first eight weeks, immediately after the infection. It usually presents with a high number of parasites circulating in the blood. The chronic 73 phase (CCD), which develops about 3 and 8 weeks after infection, can last for decades 74 75 with no or mild symptomatology and a very low parasitemia level. It is estimated that only 30% of cases develop pathognomonic symptoms of the disease (12-14). Such 76 symptoms include cardiac and/or gastrointestinal symptoms disorders (15). These 77 chronic patients (CCD) constitute the greatest epidemiological risk for disease 78 transmission in countries where infection by insect vectors does not occur. 79

Diagnostic methods vary from direct test, such as xenodiagnosis including the 80 combination with molecular techniques, (16) to immunological techniques, in which 81 different antigens (native or recombinant) are used (17,18). High variability in the 82 sensitivity and specificity among techniques has been related to, not only to the type of 83 laboratory technique or antigen used, but also to geographical differences in parasite 84 85 strains, as well as genetic differences between human populations, which may contribute to discrepancies in serological tests (19). This has led to a series of 86 recommendations by the Pan American Health Organization (PAHO) and national 87 guidelines, (20-22) recommending the confirmatory use of two serological tests in 88 parallel, with a sensitivity of at least 98% (23) for a correct diagnosis of the disease. 89 Even so, when serological tests are inconclusive, some guidelines recommend 90 91 molecular tests, such as PCR, the technique of choice for the confirmatory diagnosis of T. cruzi parasitemia (24). WHO recommends PCR as a confirmatory test after screening 92 of blood donors, in the diagnosis of acute or congenital infection, or for therapeutic 93 follow-up after diagnosis of acute infection (23). However, conventional PCR is 94

unsuitable for chronic CD diagnosis due to low parasitemia and parasite DNA blood
levels in the chronic phase, together with the different DNA extraction and purification
systems, that bring PCR sensitivity to about 50-90%, whereas its specificity stays close
to 100% (25). Due to the aforementioned drawbacks and despite its high specificity,
PCR is recommended only when serological tests are inconclusive according to the
recommendations of expert committees in different countries, such as Brazil, Chile,
USA or Spain (20–22).

Therefore, in this paper we present different methodologies, different primers, the combination of nested PCR on non-visible PCR amplicons, the use of cell-free circulating DNA (cfDNA), and the extraction of DNA from exovesicles circulating in the serum (EVs-DNA) of chronic patients in order to try to solve diagnostic problems and facilitate the detection of CD in the hospital setting.

107 MATERIAL AND METHODS

108 Human blood samples

This study was conducted at the Microbiology and Parasitology department of Hospital 109 110 Universitario y Politécnico La Fe (HUyP-La Fe), Valencia, Spain and at Parasitology department Institute of Biotecnology University of Granada Spain, from 2011 to 2020. 111 CD serologically positive serum samples screened with the LiaisonXL murex 112 chemiluminescence kit and tittered with the Trinity Biotech IFA kit were used. Samples 113 (n 448) included patients with suspected disease or with manifest symptoms. They can 114 115 be considered representative of the different groups of the population affected by CD, most of whom adults (n 313), mostly born in Bolivia, except for the children born in Spain 116 from chagasic mothers (n 135). Some corresponded to patients who had received 117 treatment for CD and who came for re-evaluation as follow-up, and patients with 118

compromised immunity with post-transplant immunosuppression therapy and one of the patients was HIV seropositive. According to sex, 302 (67.4%) patients were female and 146 (32.6%) were male. All of the patients gave written informed consent before starting the study and all protocols were approved on March 4, 2011, the study was expanded to include the use to isolate and purify exovesicles from circulating serum and cell-free DNA (cfDNA) on September 26, 2018, with registration numbers 201102400000408 and 672/CEIH/2018 respectively, by the ethical committee of Granada University.

126 **DNA isolation method from peripheral blood**.

Peripheral blood samples (5 mL) were collected in Vacutainer vacuum blood tubes with EDTA and then subjected to a specific lysis pretreatment before proceeding to the DNA isolation methods. Pretreatment consisted of mixing 1:1 blood and denaturing lysis buffer (6M guanidine hydrochloride, 10 mM urea, 10 mM TRIS-HCL, 10 mM TRIS-HCL, 20% (v/v) Triton X-100; pH was adjusted to 4.4) through brief shaking. The samples were incubated at 70°C for 10 min. Before proceeding to the next steps, the samples were kept for at least 48 h at room temperature.

The automated purification protocol of the Maxwell Blood DNA Purification kit (Promega Biotech) was chosen according to the guidelines approved by HUyP-La Fe and was used following the manufacturer's instructions. The initial volume for each of the blood sample was 400 µL of pretreated peripheral blood.

138 Isolation of circulating cell-free parasite DNA (cfDNA) from serum

For the serum samples, 5 mL of blood were taken in the BD Vacutainer SST II Advance tubes (Reference. 366468). Once vortexed for 5 min, each tube was centrifuged at 1,500 x g for 10 min and approximately 2.0 mL of serum were collected to perform the different tests.

The samples used for the assay of this protocol were 4 serum pools and two individual serum samples from patients with digestive disorders. Two pools were formed by three patients with cardiac pathology each, and two pools formed by three patients with nonspecific symptoms. (Table S1).

For the isolation of circulating DNA (cfDNA) of the parasite from the patient's serum, the 147 MagMAXTM cell-free DNA isolation kit (Thermo Fisher Scientific) was used and the 148 149 manufacturer's instructions were followed. First, the 100 µL serum pools were centrifuged at 1,600 x g 10 min at 4°C. Once the first centrifugation was completed, the 150 supernatant was subjected to a second centrifugation at the same speed and time as 151 152 the previous one in order to remove any cellular debris in the serum. Next, the proteins 153 contained in the supernatant were digested for 20 min at 60°C with 2 µL of Proteinase k (20 µg/mL). To the digestion product, 150 µL of buffer (30mTris-HCl pH 8.0, 10mM 154 155 EDTA, 1% SDS) were added together with 5 µL of magnetic bead solution. The resulting volume (255 µL) of the mixture was vortexed intensively for 10 min and then centrifuged 156 157 at 14,000 x g for 10 s. The resulting pellet was washed twice, first with 500 µL of wash 158 buffer and then with 500 µL of 80% ethanol, and subjected to centrifugation (20 s at 1,3000 x g). Finally, the pellet was dried and resuspended in 50 µL Milli-Q water. 159

160 **DNA isolation from serum exovesicles (EVs-DNA)**

To improve the detection of parasite DNA in *T. cruzi* infected patients, DNA was isolated from exovesicles (EVs) present in serum. For this assay, 25 nested PCR negative and 25 nested PCR positive samples were selected as described below.

Purification of circulating EVs from serum was performed following the methods previously described by Diaz et al. (26) and Retana et al. (27), by a mixed

ultracentrifugation-ultrafiltration procedure. For this purpose, 1 mL serum samples were 166 167 each diluted (1:1) with PBS previously ultrafiltered through 0.22 µm pore filters. The diluted samples were first centrifuged at 3,500 x g for 10 minutes (4°C) to eliminate 168 contamination by cells or cellular debris from the serum. The pellet obtained was 169 170 discarded and the supernatant was ultrafiltered through sterile 0.45 µm pore filters (Millipore, USA) in order to remove apoptotic debris and particles remaining in the 171 supernatant from the first centrifugation. It was subsequently ultracentrifuged in 172 microtubes (Hitachi No 1508) at 110,000 x g for 2 h at 4°C in a Sorwal WX80 centrifuge 173 with fixed-angle rotor (Fiberlite[™] F50L-24 × 1.5). The resulting pellet was washed three 174 times by ultracentrifugation in sterile PBS as described above and evaluated by 175 176 transmission electron microscopy and NTA nanoparticle tracking analysis, as described 177 in a previous paper (28).

178 For the isolation of DNA from EVs-DNA, the method described by Orrego et al. in 2020 was followed. To do so, the sediment containing EVs from serum was treated with a 179 total of 2 units of DNAase I at 37°C for 30 min to remove external DNA from the EVs. 180 181 After treatment, the enzyme was inactivated with heat at 70°C in a solution containing 50 mM EDTA. After removal of free nucleic acids from the EVs suspension, 100 µL of 182 EVs were lysed with 200 µL of lysis buffer (30 mMTris-HCl pH 8.0, 10 mM EDTA, 1% 183 SDS) supplemented with 20 µL of proteinase K (0.1 mg/mL), shaken by vigorous 184 pipetting and incubated at 56°C for 1 h. Finally, nucleic acid purification and precipitation 185 186 were performed following the traditional phenol-chloroform method by mixing 320 µL of lysed EVs suspension with 320 µL of phenol-chloroform-isoamyl reagent, 25:24:1 (v/v) 187 (Sigma). The mixture was shaken briefly and centrifuged at 14,000 x g for 10 min. The 188 aqueous phase was then collected and the DNA was precipitated with 1/10 vol of 3M 189

sodium acetate pH 5 and 2.5 vol of HPLC grade absolute ethanol. The mixture was
incubated overnight at -20°C and centrifuged at 15,000 x g for 10 min at 4°C, the
supernatant was discarded and the precipitate was washed twice with cold 70% ethanol.
Finally, the pellet was dried in a Jouan Thermo speed Vac (RC1010) at 20°C and diluted
in 20 µl Milli-Q water.

195 Transmission electron microscopy

To corroborate by electron microscopy the purification of EVs from serum, the 196 ultracentrifuged button resulting from the purification process described above was fixed 197 for 2h at room temperature in 2.5% glutaraldehyde in cacodylate buffer pH 7.2 and then 198 199 resuspended in PBS for sample processing by negative staining. For this purpose, 200 approximately 15 µL of the suspension were deposited on nickel 300 mesh grids, coated with a charcoal layer, for 10 min. The grids were then washed twice with ultrapure water 201 202 for 1 min. The grids were negatively stained with 1% uranyl acetate for 1 min. After staining, the samples were dried on filter paper and observed under a Zeiss Libra 120 203 Plus transmission electron microscope at 120KV at the Centro de Instrumentación 204 205 Científica (University of Granada facilities).

206 Detection of *T. cruzi* DNA in biological samples by different PCR strategies

207 Genes used in the study

In this work, two specific, conserved and highly repeated genes in the *T. cruzi* genome, widely used in the diagnosis of Chagas disease, were analyzed: the kinetoplast DNA (kDNA) minirepeat regions, which represent the major sequence component of kDNA with about 120,000 copies per parasite (29,30), and the nuclear satellite DNA with 10^4 to 10^5 copies in the highly conserved parasite genome (31).

213 PCR strategies

214 The kDNA minirepeat regions and nested PCR

215 DNA from the 448 serologically positive samples, extracted using the Maxwell Blood DNA Purification Kit automated protocol (Promega Biotech), and the minirepeated 216 region of the kDNA was amplified. The reaction mixture was made up of Go Tag1flexi 217 218 1X amplification buffer (25 mM dNTPs, 2.5 mM MgCl₂, 1.0 U of Go Tag1(Promega, USA), 10 pmol of specific primers 121F and 122R (Table 1) and 10 µL of template. The 219 final volume was 50 µL according to the methodology described previously (32). 220 Amplification conditions consisted of two cycles, each of 1 min at 98°C and 2 min at 221 64°C, followed by 33 cycles of 1 min at 94°C, and 1 min at 64°C, before a final extension 222 at 72°C for 10 min. In all cases, a DNA sample of *T. cruzi* from the culture as a positive 223 224 control and a non-template control were used.

225	Table 1	. Sequ	iences (of I	primers	used	in	this	stud
225		. Sequ	iences (ן וט	primers	useu	111	แทร	Sluc

226

Name	5'→3' Sequence	Tm (°C) Type	Type (5'→3')	Product length (bp)
SATF	GCAGTCGGCKGATCGTTTTCG	60.1 PCR	F	120
SATR	TTCAGRGTTGTTTGGTGTCCAGTG	58.5 PCR	R	
121F	AAATAATGTACCGGKGAGATGCATGA	65 PCR	F	330
122R	GGTTCGATTGGGGTTGGTGTAATATA	66 PCR	R	
Т3	TC TTT GGT GTG ATC GTT AC	58 nested PCR	F	150
T4	TAC ATT CTA TTT CTT CTC TG	52 nested PCR	R	

In all instances, the amplification result, although not visible on DNA electrophoresis, was subjected to nested PCR amplification. To this end, 2 μ L of PCR product were used as template, 0.2 μ M concentration of T3 and T4 primers (Table 1), 0.2 mM of each dNTP, 3 mM MgCL₂, 0.5 μ L of GoTaq® Flexi DNA Polymerase and the final volume was 50 μ L. The nested PCR conditions were (1) 94°C 5 min, (2) (94°C 1 min, 48°C 1 min, 72°C 1 min) × 35, (3) 72°C 7 min, (4) 12°C indefinite. Amplifications were performed on a GeneAmp PCR System 9700 thermal cycler, AB Applied Biosystems and the nested PCR amplification product was sequenced on a GenomeLab GeXP system. The results obtained from sequencing were aligned using BLAST programs and the identity and coverage of these sequences were studied.

237 EVs-DNA and cfDNA PCR

Both the EVs-DNA present in the serum and the cfDNA were amplified indistinctly with 238 the primer pair 121F-122R corresponding to the kDNA and with the SATF and SATR 239 primers for the nuclear satellite regions (Table 1) using for these amplifications 0, 5 µM 240 of the primers, 0.2 mM of each dNTP, 2.5 mM MgCl₂, 0.005 µL DMSO, 0.125 µL GoTaq 241 Flexi DNA Polymerase enzyme and 2 µL as DNA template from DNA purification, the 242 final reaction volume was 25 µL. For the SAT primers, the protocol was (1) 95°C 5 min, 243 (2) (94°C 10 sec, 65°C 10 sec, 72°C 10 sec) × 40, (3) 72°C 5 min, (4). Samples were 244 245 kept at 12°C.

The final products were visualized on a 2% agarose gel stained with Safe Sybr and developed on a ChemiDoc MP Imaging System (Biorad). Electrophoresis was performed at 100 mV for 30 min.

249 RESULTS

250 Amplification of DNA from peripheral blood

The sera of 448 immunologically positive subjects, as indicated above, came from patients who had visited the different medical services of the Hospital La Fe; 67.4% corresponded to samples from female patients and 146 samples to males (32.6%). The majority (313) of whom were born in American countries, mostly in Bolivia. While 135, namely the youngest, were born in Spain but of Latin American mothers.

Figure 1A shows the results of the first PCR with amplicons of 330 bp. Nested PCR (corresponding to the kDNA) gave a positive result for 72 (16%) samples in which the 150 bp amplicon was visible in agarose electrophoresis (Figure 1 B). Sequencing results of this amplicon are shown in Figure 1 C. The results of the NCBI BLAST analysis of these sequences verified that the amplicon corresponded to a kDNA region of *T. cruzi*, 150 bp with coverage of 93% and an E of 2e-44 and an identity percentage of 97.4% (Figure 1 C).

Figure 1. A: 2% agarose gel analysis of PCR-amplified products showing a 330 pb with 121 and 122 primers. PCR performed with peripheral blood DNA. Line 1, Hipper ladder II, Line 2, positive control, line 3 to 20 samples from 1 to 18 patients consecutively. B: 2% agarose gel showing a 150 pb band which belongs to nested PCR performed with T3 and T4 primers. C: Sequence alignment using as reference sequence the kDNA *T. cruzi* sequence with accession number DQ835656.

Analysis of the 72 samples, in which sample positivity was verified by nested PCR, resulted in 49 patients being female and 23 males. Mean age was 36.6 years (35 median) for females and 35.7 years (34 median) for males. Furthermore, positive patients were classified into 4 age ranges as shown in Table S2. Thirty-four (5.6%) women were of childbearing age and 17 of whom were pregnant. Also, *T. cruzi* DNA was detected in the peripheral blood sample in the three children who were between 0 to 2 years old.

Most of CD patients were born in Bolivia (n 70), one patient was from El Salvador and another one from Ecuador. Table S3 shows the distribution of origin in Bolivia, with Santa Cruz being the most represented region with 44.2% of the patients, followed by

Sucre with 12.8%, Cochabamba with 10%, Potosí with 5.7%, La Paz (1.4%), Tarija (1.4%) and unidentified regions 25.2%.

Table S1 shows the conditions and age corresponding to the 72 positive nested PCR patients used in the study. Most of whom presented indeterminate symptoms (n 53), two had digestive disorders and nine patients suffered heart conditions. Of the total 72 samples, 25 corresponded to patients who had not yet been treated with benznidazole, and it is noteworthy that of the 47 that had been treated only three remained PCR positive for *T. cruzi*.

287 DNA serum EVs and cfDNA amplification

288 Confirmation of circulating serum EVs

TEM visualization of EVs from serums pool isolated by ultracentrifugation is shown in 289 Figure 2A. The mean size of the EVs was 119.92 ±18.41 nm. NTA analysis (Figure 2 B) 290 291 revealed the different populations of these EVs in which the majority peak revealed a size of 163 nm. A second population less numerous of EVs with an average size of 231 292 293 nm was observed. Analysis of the total population of EVs showed a mode size of 294 208±84.8 nm and the mode was 163 nm. Also, few populations of larger size were observed which could be considered aggregates of the EVs purified from the circulating 295 EVs in the serum of the patients studied. 296

Figure 2. EVs characterization. A: isolated serum pool EVs observed under TEM. B;
NTA showing the EVs populations.

299 Liquid biopsy

A total of 50 sera selected from the initial 448 serologically positive patients were used for these experiments. Twenty-five of these corresponded to patients who were not positive by nested PCR, while the remaining 25 sera were from patients positive by nested PCR. Serum EV DNA (EVs-DNA) and circulating free cellular DNA (cfDNA) were
 purified from the selected samples.

305 To perform PCR and as indicated in the Material and methods section, primers 121F-

122R and those corresponding to SAT satellite DNA were used indistinctly with the DNA

307 purified by these methods.

308 PCR analysis using DNA-EVs

The results of parasite EVs-DNA circulating in serum showed that twenty-five patients were positive for primers 121F-122R (Figure 3 A) and all but one (24) were positive for SAT primers (Figure 3 B).

Figure 3. 2% agarose gel electrophoresis analysis of PCR-amplified products. A: PCR performed with 121 and 122 primers and EVs-DNA. Line M, Hipper ladder II; Line 6, C+, positive control; line 2 to 5 and lines 7 to 11 samples of patients. B: PCR performed with SAT primers and EVs-DNA. Line M, Marker, Line 2, positive control; line 3 to 10 samples 1, 8, 10, 12, 13, 14, 15, 16, 19, 21 respectively. C: PCR performed with SAT primers and cfDNA. Line C+, positive control; Line C- non-template control; Line 3 to 5 samples 1a, 2a, 3a; line 6 non-template control; line 7 to 9 samples 1b, 2b, 3b.

319 PCR analysis using cfDNA

Isolated cfDNA was amplified by PCR with SAT primers. Figure 3 C shows six positive samples (Table S1) corresponding to chagasic patients with cardiac, digestive and indeterminate conditions. The same samples were negative when amplified by PCR with primers 121F-122R.

324 DISCUSSION

In the last decades, the distribution of CD has spread due to human migration for economic reasons from geographical areas of Central and South America, where

hematophagous vector transmission is still the case, to non-endemic areas of North 327 328 America, Europe, Japan or Australia. Spain, Italy and Switzerland are the three European countries (33) with highest levels of Latin American communities, especially 329 Spain, related to their common language as well as historical and cultural links. The 330 health authorities in Spain and Tuscany (Italy), areas with a high level of Latin American 331 migrants have therefore adopted standards and recommendations on hemodonations 332 333 (34), and transplant donors with regard to the detection of chagasic patients in order to prevent human-to-human transmission of the disease (2,35). Similarly, regulations have 334 been adopted for the screening of pregnant women originating from endemic countries 335 and for which both the mother's and newborn's blood are tested (36,37) in order to 336 establish a treatment, which is well tolerated and effective in this type of patient. All this 337 has prompted the standardization of diagnostic methods for CD in health centers and 338 especially for chronically ill patients, in whom parasitemia levels are practically non-339 existent. 340

Classical parasitological diagnostic methods, such as visualization of trypomastigote 341 342 forms in blood smears or thick drop, or even trypomastigote concentration techniques by centrifugation in microhematocrit tubes, have been used to diagnose CD (38) (39). They 343 show high specificity but very low sensitivity, especially in chronic patients. These 344 methods may be applicable in diagnosis when the disease is developed with high 345 parasitemia in the acute phase or after reactivation of circulating parasitemia in 346 347 immunosuppressed chronic patients (38). Only culture and xenodiagnosis can be used to directly detect T. cruzi infections in the chronic phase. But these techniques are not 348 useful in clinical practice, especially in Europe, due to the limitations of insect vector 349 handling and the delay in obtaining results, which limits their usefulness in diagnostic 350

studies and in evaluating treatment efficacy (40,41). Moreover, the evaluation of different
 techniques shows that in the case of parasitemia, PCR is at least 27 times more
 sensitive than blood culture (42).

The course of the disease is characterized by elevated IgM levels during the initial acute 354 355 phase of the disease and the appearance of IgGs that persist throughout the disease (43). Thus, immunological diagnostic techniques are the gold standard for the diagnosis 356 of CD in chronic patients, even in asymptomatic cases. The limiting factors in serological 357 studies are the possible cross-reactivity with Leishmania spp. or Trypanosoma rangeli 358 infections in those geographical areas where the disease was acquired and these 359 trypanosomatids coexist (40,44). Another drawback could be the lack of sensitivity to the 360 361 different parasite strains that affect humans throughout the Americas. They may present antigenic variability, which requires, if possible, the use of antigens of different 362 geographical origin and different nature (19,45) according to the recommendations of 363 the different committees on CD. Individuals are considered infected when they have a 364 365 positive result in at least two serological techniques using different antigens. A third 366 technique is required in case of discrepancy of indeterminate immunological results (20-23), or the use of a mixture of antigens that minimize discrepancies (17,46). The other 367 significant case that invalidates immunological techniques is the diagnosis in newborns 368 from infected mothers due to the presence of IgGs from the mother to the fetus by 369 transplacental transfer (42,47–49). 370

In cases that require the detection of the direct presence of the parasite in blood, when doubtful or inconsistent serological results are obtained and when the efficacy of the patient's treatment is evaluated, PCR methods capable of detecting the presence of parasite nucleic acids in blood (50) are needed to determine the unequivocal presence

of the parasite. However, this technique, has a number of limitations that can alter the results and that must be considered (51,52) such us the volume of blood processed, the correct handling of the blood (use of the chaotropic agent guanidine, time and treatment of the lysis process), the manual or automatic DNA extraction procedures, the presence and especially the elimination of PCR inhibitors, the primers used, etc. For all of these reasons, the quest for new procedures and methodologies in the extraction of nucleic acids to be applied to minimize false negative results continues.

The samples reflect the Latin American population living and working in the area of influence of the Hospital La Fe in Valencia. Data from INE (National Institute of Statistics) for the year 2021 show that 17,847 people born in Bolivia reside in the Valencian Community, 39.1% are male and 60.9% are female.

A nested PCR was performed on all the samples, in which the primers T3 and T4 386 designed for this purpose were used and which would amplify a band of 150 bp from the 387 internal zone of the amplicon produced in the first PCR. The use of nested PCR using 388 other genes with the products of the first PCR was already studied by Pereira et al. (53) 389 390 and Ribeiro et al. (54), who concluded that the sensitivity of a series of 3 nested PCRs using primers specific for conserved regions of the Kinetoplast is able to detect 1 391 parasite per ml of blood, increasing the sensitivity of the PCR by about 10,000 times. 392 Other authors such as Marcon et al., 2002 (26), or Riera et al., 2006 (55) employed 393 nested PCR after conventional PCR using TCZ1 and TCZ2 and internal primers TCZ3 394 395 and TCZ4 to evidence parasitization in a neonate. Also, Pereira et al., 2016 (53) used nested PCR for the products of a PCR using the TCZ1 and TCZ2 primers previously 396 mentioned to detect CD positivity in a population of elderly people suffering from cardiac 397

398 problems and in whom the involvement of *T. cruzi* in these pathologies was not 399 suspected.

400 Sixteen percent of the total 448 immunologically positive patients tested positive in 401 nested PCR.

The amplicons obtained were visualized by electrophoresis resulting in a band of 150 bp. Sequencing of the amplicons showed that they correspond to an internal region of the *T. cruzi* kDNA described by Burgos et al. (56), with a coverage of 93% and a percentage of identity of 97.4%, Figure (1).

The treatment of choice usually prescribed for CD-positive patients in Spain consists of 5 mg/kg benznidazole (BZ; N-benzyl-2-nitroimidazole acetamide) daily for 60 days. It is noteworthy that, of the 47 selected patients who had been treated, three tested positive post-treatment in nested PCR for *T. cruzi*. It was not ruled out that the treatment was not completed as a consequence of the side effects involved and the consequent interruption by the patient, and in one case the patient stated that he had returned to his country, not ruling out reinfection.

413 We also evaluated whether cfDNA present in the serum of CCD patients could be used as a template for specific PCRs to improve diagnosis in CCD and in neonates where 414 parasitaemia is very low and almost undetectable by other diagnostic procedures. The 415 results of the analysis were 100% positive. This confirms that serum is a good sample to 416 carry out DNA extraction to be used in the PCR detection of *T. cruzi*, which was already 417 418 determined by Russomando et al. (57) and in the review carried out by Weerakoon et al. (58) where the use of cfDNA in different biological samples in the diagnosis of different 419 420 parasitoses was encouraged.

The results obtained in our cfDNA (nuclear DNA or mitochondrial KDNA) of parasitic 421 422 origin would come from circulating parasites coming from either lysis or apoptosis of free or intracellular parasitic forms, or transported in elements secreted by the parasitic 423 forms. With these sera we proceeded to the purification of EVs circulating in the serum, 424 425 and the purification of the EVs from the serums of the patients was evidenced both by electron microscopy and by NTA. The term EVs designates the set of various EVs 426 released by cells and delimited by a lipid bilayer that are released into the extracellular 427 space by prokaryotic and eukaryotic cells (59). EVs constitute cellular mechanisms of 428 cell-to-cell communication over short or long distances between cells acting as 429 endocrine, paracrine, juxtacrine or autocrine signaling (27), through uptake of EVs or 430 receptor-mediated interactions. Evidently, blood is the mechanism of transport and 431 diffusion of these EVs. EVs are classified by their size, biogenesis and composition, 432 exosomes with sizes between 20 to 200 nm, ectosomes between 200 to 1000 nm and 433 apoptotic vesicles of a larger size (60). Exosomes contain functional molecules 434 (including proteins, nucleic acids and lipids) derived from their cells of origin, being 435 436 present in all biological fluids where they have been sought, urine and saliva and undoubtedly in blood (61-63). Due to the protection of the lipid bilayer, exosomes are 437 relatively stable and proteins and other molecules transported in these small vesicles 438 are protected from degradation. Their composition is guite complex, including a wide 439 variety of lipids, proteins, different populations of RNAs, ssDNA, and metabolites (28). 440 Typically, the internal volume of an exosome ranges from 20 to 90 nm³, suggesting that 441 a prototypical exosome would contain approximately 100 proteins and 10,000 442 nucleotides (64). 443

Two PCRs were performed with the DNA extracted from the serum EVs, one with the primers (121F-122R) and the other PCR with the SATF and SATR primers; with the former, 50% positivity was obtained and with the SATF and SATR primers, 48% of the patients were positive.

The presence of parasite EVs in the serum of patients with CD was already described by some of us in 2017 (26) and these EVs appeared circulating in the serum forming immunocomplexes in patients with different Chagas pathologies, which denoted the presence of metabolically active forms of the parasite and capable of actively releasing these EVs.

EVs have been employed as liquid biopsy in numerous assays for tumor diagnosis (65-453 454 67), however the use of EVs-DNA for the diagnosis of pathogens and especially intracellular pathogens has hardly been addressed so far. Cho et al., 2020 (68) showed 455 that PCR using exosome DNA from isolates of patients affected by tuberculosis shows 456 higher sensitivity than conventional PCR diagnosis using total DNA for PCR. To our 457 knowledge, this is the first study to report the detection of T. cruzi DNA from circulating 458 459 EVs in the serum of patients using two sets of primers, i.e., those that detect kinetoplast DNA minicircles (121F-122R) and those that recognize nuclear DNA with the SATF and 460 461 SATR primers.

From the results of the present work, it is evident that both cfDNA and EVs-DNA from the serum of infected patients constitute useful and effective biological samples to demonstrate, by PCR using conventional primers, the active presence of the parasite, in clinical cases (neonates and studies of the efficacy of treatment) where it is necessary to demonstrate the presence of the parasite.

467 FUNDING AND ACKNOWLEDGMENTS

This research was funded by the ERANet program, Research in prevention of congenital 468 Chagas disease: parasitological, placental and immunological markers (ERANet17/HLH-469 0142 (Cochaco). Instituto Carlos III, Ministerio de Sanidad, Gobierno de España; 470 Fundación Ramón Areces "Interactoma de las exovesículas de T. cruzi y de los 471 inmunocomplejos que forman con las células del hospedador: implicaciones en la 472 patología de la enfermedad de Chagas (2019)". Ministerio de Ciencia y Tecnología of 473 the government of Spain funded the project PGC2018-099424-B-I00 and The financial 474 support given by the proyect A-BIO-350-UGR18 I+D+i Proyect "Programa Operativo 475 FEDER de Andalucía JJAA" 2014-2020. 476

- 477 CONFLICTS OF INTEREST
- The authors declare no conflict of interest.

479 REFERENCES

- Moncayo A. Chagas disease: current epidemiological trends after the interruption of
 vectorial and transfusional transmission in the Southern Cone countries. Mem Inst
 Oswaldo Cruz. 2003;98(5):577–91.
- Pati I, Cruciani M, Masiello F, Barone F, Silvioli G, La Raja M, et al. Chagas Disease
 and Transfusion Risk in Italy: The Results of a National Survey. Pathogens.
 2022;11(11):1229.
- 3. Kemmerling U, Osuna A, Schijman AG, Truyens C. Congenital Transmission of *Trypanosoma cruzi*: A Review About the Interactions Between the Parasite, the
 Placenta, the Maternal and the Fetal/Neonatal Immune Responses. Front Microbiol.
 2019;10:1854.

- 490 4. Coura JR, Dias JC. Epidemiology, control and surveillance of Chagas disease: 100
 491 years after its discovery. 2009;104:31–40.
- 492 5. World Health Organization. Regional Office for South-East Asia. (2021). Strategic
- 493 Framework for the South-East Asia Regional Vaccine Action Plan 2022–2030 as
- 494 aligned with the global Immunization Agenda 2030. World Health Organization.
- 495 Regional Office for South-East Asia. https://apps.who.int/iris/handle/10665/343756
- 496 6. Tanowitz HB, Weiss LM, Montgomery SP. Chagas Disease Has Now Gone Global.
 497 PLoS Negl Trop Dis. 2011 Apr 26;5(4):e1136.
- 7. Requena-Méndez A, Albajar-Viñas P, Angheben A, Chiodini P, Gascón J, Muñoz J,
 et al. Health Policies to Control Chagas Disease Transmission in European
 Countries. PLoS Negl Trop Dis. 2014 Oct 30;8(10):e3245.
- 8. Ramos JM, Milla A, Rodríguez JC, López-Chejade P, Flóres M, Rodríguez JM, et al.
 Chagas disease in Latin American pregnant immigrants: experience in a nonendemic country. Arch Gynecol Obstet. 2012 Apr 1;285(4):919–923.
- 504 9. Kransdorf EP, Zakowski PC, Kobashigawa JA. Chagas disease in solid organ and
 505 heart transplantation. Curr Opin Infect Dis. 2014;27(5):418–424.
- 10. Balderramo D, Bonisconti F, Alcaraz A, Giordano E, Sánchez A, Barrabino M, et al.
 Chagas disease and liver transplantation: Experience in Argentina using real-time
 quantitative PCR for early detection and treatment. Transpl Infect Dis. 2017 Dec
 1;19(6):e12782.

- 510 11. Pierrotti LC, Carvalho NB, Amorin JP, Pascual J, Kotton CN, López-Vélez R. Chagas
- 511 Disease Recommendations for Solid-Organ Transplant Recipients and Donors.
- 512 Transplantation. 2018;102(2S):S1–7.
- 513 12. Kirchhoff L. Chagas disease. American trypanosomiasis. Infect Dis Clin North Am.
 514 1993;7(3):487–502.
- 515 13. Coura JR. Chagas disease: what is known and what is needed A background
 516 article. Mem Inst Oswaldo Cruz. 2007;112(1).

517 14. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis.
518 2001 Sep 1;1(2):92–100.

15. Messenger LA, Miles MA, Bern C. Between a bug and a hard place: *Trypanosoma cruzi* genetic diversity and the clinical outcomes of Chagas disease. Expert Rev Anti
 Infect Ther. 2015 Aug 3;13(8):995–1029.

522 16. Zulantay I, Apt W, Gil LC, Rocha C, Mundaca K, Solari A, et al. The PCR-based
523 detection of *Trypanosoma cruzi* in the faeces of Triatoma infestans fed on patients
524 with chronic American trypanosomiasis gives higher sensitivity and a quicker result
525 than routine xenodiagnosis. Ann Trop Med Parasitol. 2007 Dec 1;101(8):673–679.

17. De Marchi CR., Di Noia JM., Frasch AC., Amato Neto V, Almeida IC., Buscaglia CA.
Evaluation of a Recombinant *Trypanosoma cruzi* Mucin-Like Antigen for
Serodiagnosis of Chagas' Disease. Clin Vaccine Immunol. 2011 Nov 1;18(11):1850–
1855.

530	18. Afonso AM, Ebell MH, Tarleton RL. A Systematic Review of High Quality Diagnostic
531	Tests for Chagas Disease. PLoS Negl Trop Dis. 2012 Nov 8;6(11):e1881.
532	19. Truyens C, Dumonteil E, Alger J, Cafferata ML, Ciganda A, Gibbons L, et al.
533	Geographic Variations in Test Reactivity for the Serological Diagnosis of
534	<i>Trypanosoma cruzi</i> Infection. J Clin Microbiol. 2021 Nov 18;59(12):e0106221.
535	20. Pinto Dias JC, Novaes Ramos AJ, Dias Gontijo E, Shikanai-Yasuda MA, Rodrigues
536	Coura J, Morais Torres R, et al. Brazilian Consensus on Chagas disease. Rev Soc
537	Bras Med Trop. 2005;38(3):7–29.
538	21. Bern C, Montgomery SP, Herwaldt BL, Rassi A, Marin-Neto JA, Dantas RO, et al.
539	Evaluation and Treatment of Chagas Disease in the United States. A Systematic
540	Review. JAMA. 2007 Nov 14;298(18):2171–2181.
541	22. Apt W, Heitmann I, Jercic MI, Jofré L, Muñoz P, Noemí I, et al. Guías clínicas de la
542	enfermedad de Chagas 2006: Parte V. Diagnóstico de laboratorio. Rev Chil Infectol.
543	2008;25:378–383.
544	23. World Health Organization (WHO). Control of Chagas disease : second report of
545	the WHO expert committee. Technical Report 109. Geneva: WHO; 2002.
546	http://whqlibdoc.who.int/trs/WHO_TRS_905.pdf
547	24. Murray KO, Saldaña MA, Gunter SM, Manzanero R, Zielinski-Gutierrez E, Herrera C,
548	et al. Diagnosis of Acute Chagas Disease in a Belizean Child with Evidence of a

549 Multiclonal *Trypanosoma cruzi* Infection. Am J Trop Med Hyg. 2022 Nov 550 14;107(5):992–995.

25. Brasil PE, De Castro L, Hasslocher-Moreno AM, Sangenis LH, Braga JU. ELISA
 versus PCR for diagnosis of chronic Chagas disease: systematic review and meta analysis. BMC Infect Dis. 2010 Nov 25;10(1):337.

26. Díaz Lozano IM, De Pablos LM, Longhi SA, Zago MP, Schijman AG, Osuna A.
Immune complexes in chronic Chagas disease patients are formed by exovesicles
from *Trypanosoma cruzi* carrying the conserved MASP N-terminal region. Sci Rep.
2017 Mar 15;7:44451–44451.

27. Retana Moreira L, Rodríguez Serrano F, Osuna A. Extracellular vesicles of
 Trypanosoma cruzi tissue-culture cell-derived trypomastigotes: Induction of
 physiological changes in non-parasitized culture cells. PLoS Negl Trop Dis. 2019
 Feb 21;13(2):e0007163.

28. Retana Moreira L, Prescilla-Ledezma A, Cornet-Gomez A, Linares F, Jódar-Reyes
AB, Fernandez J, et al. Biophysical and Biochemical Comparison of Extracellular
Vesicles Produced by Infective and Non-Infective Stages of *Trypanosoma cruzi*. Int J
Mol Sci. 2021;22(10).

29. Degrave W, Fragoso SP, Britto C, van Heuverswyn H, Kidane GZ, Cardoso MAB, et
 al. Peculiar sequence organization of kinetoplast DNA minicircles from *Trypanosoma cruzi*. Mol Biochem Parasitol. 1988 Jan 1;27(1):63–70.

30. Vergara C, Muñoz G, Martínez G, Apt W, Zulantay I. Detection of *Trypanosoma cruzi*by PCR in adults with chronic Chagas disease treated with nifurtimox. PLOS ONE.
2019 Aug 21;14(8):e0221100.

31. Duffy T, Bisio M, Altcheh J, Burgos JM, Diez M, Levin MJ, et al. Accurate Real-Time
 PCR Strategy for Monitoring Bloodstream Parasitic Loads in Chagas Disease
 Patients. PLoS Negl Trop Dis. 2009 Apr 21;3(4):e419.

32. Ledezma AP, Blandon R, Schijman AG, Benatar A, Saldaña A, Osuna A. Mixed
infections by different *Trypanosoma cruzi* discrete typing units among Chagas
disease patients in an endemic community in Panama. PLOS ONE. 2020 Nov
12;15(11):e0241921.

33. World Health Organization (WHO). Control and prevention of Chagas disease in
Europe. Report of a WHO Informal Consultation (jointly organized by WHO
headquarters and the WHO Regional Office for Europe) Geneva, Switzerland, 17–18
December 2009. Geneva: WHO; 2010. Report No: WHO/HTM/NTD/IDM/2010.1
http://www.fac.org.ar/1/comites/chagas/Chagas_WHO_Technical%20Report_16_06
_10.pdf

585 34. Real Decreto 1088/2005, de 16 de septiembre, por el que se establecen los 586 requisitos técnicos y condiciones mínimas de la hemodonación y de los centros y servicios de transfusión. [Royal Decree 1088/2005 of 16 September establishing the 587 588 minimum technical requisites and conditions for blood donation and for blood transfusion centres and services]. Boletín Oficial del Estado. 2005;225:31288-304. 589 Madrid: Ministerio de Sanidad Consumo; 2005. 590 y http://www.boe.es/boe/dias/2005/09/20/pdfs/A31288-31304.pdf. Spanish. 35. Abras 591 A, Ballart C, Fernández-Arévalo A, Pinazo MJ, Gascón J, Muñoz C, et al. Worldwide 592 Control and Management of Chagas Disease in a New Era of Globalization: a Close 593

Look at Congenital *Trypanosoma cruzi* Infection. Clin Microbiol Rev. 2022 Mar
3;35(2):e00152-21.

36. Autonomous Government of Catalonia. Protocol for screening and diagnosing
Chagas disease in pregnant Latin American women and their newborns.
Departament de Salut, Genaralitat de Catalunya; 2010.
http://www.gencat.cat/salut/depsalut/html/en/dir3559/chagasprot_eng.pdf

37. Consellería de Sanitat de la Generalitat Valenciana. [Control regulation of congenital and perinatal infections in Valencia Community]. Regulación del control de las infecciones congénitas y perinatales en la Comunidat Valenciana. Circular 3/2007, 8-1-8/8. 2007. http://www.sp.san.gva.es/DgspPortal/docs/CIRCULAR_3_2007.pdf.
Spanish.

38. Maldonado C, Albano S, Vettorazzi L, Salomone O, Zlocowski JC, Abiega C, et al.
Using polymerase chain reaction in early diagnosis of re-activated *Trypanosoma cruzi* infection after heart transplantation. J Heart Lung Transplant. 2004 Dec
1;23(12):1345–1348.

39. Feilij H, Muller L, Gonzalez Cappa SM. Direct micromethod for diagnosis of acute
and congenital Chagas' disease. J Clin Microbiol. 1983 Aug 1;18(2):327–330.

40. Gomes YM, Lorena VM, Luquetti AO. Diagnosis of Chagas disease: what has been
achieved? What remains to be done with regard to diagnosis and follow up studies?
2009;104(1):115–121.

614	41. das Neves-Pinto AY, da Costa-Valente V, Coura JR, Aldo-da Silva Valente S,
615	Verissimo-Junqueira AC, Santos LC, et al. Clinical Follow-Up of Responses to
616	Treatment with Benznidazol in Amazon: A Cohort Study of Acute Chagas Disease.
617	PLOS ONE. 2013 May 27;8(5):e64450.
618	42. Mora MC, Sanchez-Negrette O, Marco D, Barrio A, Ciaccio M, Segura MA, et al.
619	Early diagnosis of congenital Trypanosoma cruzi infection using PCR, hemoculture,
620	and capillary concentration, as compared with delayed serology. J Parasitol. 2005
621	Dec 1;91(6):1468–1473.
622	43. Umezawa ES, Shikanai-Yasuda MA, Gruber A, Pereira-Chioccola VL, Zingales B.
623	Trypanosoma cruzi defined antigens in the serological evaluation of an outbreak of
624	acute Chagas disease in Brazil (Catolé do Rocha, Paraíba). Mem Inst Oswaldo
625	Cruz. 1996 Feb;91(1):87–93.
626	44. Wincker P, Britto C, Pereira JB, Cardoso MA, Oelemann W, Morel CM. Use of a
627	Simplified Polymerase Chain Reaction Procedure to Detect Trypanosoma cruzi in
628	Blood Samples from Chronic Chagasic Patients in a Rural Endemic Area. Am J Trop
629	Med Hyg. 1994 Dec 1;51(6):771–777.
630	45. Zingales B. Trypanosoma cruzi genetic diversity: Something new for something
631	known about Chagas disease manifestations, serodiagnosis and drug sensitivity.
632	Recent Adv Genet Mol Diagn Parasit Protozoa. 2018 Aug 1;184:38–52.

46. Del-Rei RP, Leony LM, Celedon PAF, Zanchin NIT, Reis MG dos, Gomes Y de M, et
al. Detection of anti-*Trypanosoma cruzi* antibodies by chimeric antigens in chronic

Chagas disease-individuals from endemic South American countries. PLOS ONE.
2019 Apr 18;14(4):e0215623.

47. Blanco SB, Segura EL, Cura EN, Chuit R, Tulian L, Flores I, et al. Congenital
 transmission of *Trypanosoma cruzi*: an operational outline for detecting and treating
 infected infants in north-western Argentina. Trop Med Int Health. 2000 Apr;5(4):293–
 301.

48. Mallimaci MC, Sosa-Estani S, Russomando G, Sanchez Z, Sijvarger C, Alvarez IM,
et al. Early Diagnosis of Congenital *Trypanosoma cruzi* Infection, Using Shed Acute
Phase Antigen, in Ushuaia, Tierra del Fuego, Argentina. Am Soc Trop Med Hyg.
2010 Jan 1;82(1):55–59.

49. Piron M, Fisa R, Casamitjana N, López-Chejade P, Puig L, Vergés M, et al.
Development of a real-time PCR assay for *Trypanosoma cruzi* detection in blood
samples. Acta Trop. 2007 Sep 1;103(3):195–200.

50. Marcon GEB, Andrade PD, de Albuquerque DM, Wanderley J da S, de Almeida EA,
Guariento ME, et al. Use of a nested polymerase chain reaction (N-PCR) to detect *Trypanosoma cruzi* in blood samples from chronic chagasic patients and patients
with doubtful serologies. Diagn Microbiol Infect Dis. 2002 May 1;43(1):39–43.

51. Diez M, Favaloro L, Bertolotti A, Burgos JM, Vigliano C, Lastra MP, et al. Usefulness
of PCR Strategies For Early Diagnosis of Chagas' Disease Reactivation and
Treatment Follow-Up in Heart Transplantation. Am J Transplant. 2007
Jun;7(6):1633–1640.

52. Junqueira ACV, Chiari E, Whicker P. Comparison of the polymerase chain reaction
with two classical parasitological methods for the diagnosis of Chagas disease in an
endemic region of north-eastern Brazil. Trans R Soc Trop Med Hyg. 1996
Mar;90(2):129–132.

53. Pereira MB, Batista AM, Aguiar C, Marcon GEB, Martins LC, Guariento ME, et al.
The detection of *Trypanosoma cruzi* by nested-PCR in elderly patients: relationship
to the clinical and epidemiological profile. Pathog Glob Health. 2016 Aug
17;110(6):228–232.

54. Ribeiro-Dos-Santos G, Nishiya AS. An improved, PCR-based strategy for the
detection of *Trypanosoma cruzi* in human blood samples. Ann Trop Med Parasitol.
1999 Oct 1;93(7):689–694.

55. Riera C, Guarro A, Kassab HE, Jorba JM, Castro M, Angrill R, et al. Congenital
transmission of *Trypanosoma cruzi* in Europe (Spain): a case report. Am J Trop Med
Hyg. 2006 Dec;75(6):1078–1081.

56. Burgos JM, Altcheh J, Petrucelli N, Bisio M, Levin MJ, Freilij H, et al. Molecular
diagnosis and treatment monitoring of congenital transmission of *Trypanosoma cruzi*to twins of a triplet delivery. Diagn Microbiol Infect Dis. 2009 Sep 1;65(1):58–61.

57. Russomando G, Figueredo A, Almirón M, Sakamoto M, Morita K. Polymerase chain
reaction-based detection of *Trypanosoma cruzi* DNA in serum. J Clin Microbiol. 1992
Nov;30(11):2864–2868.

676	58. Weerakoon KG, McManus DP. Cell-Free DNA as a Diagnostic Tool for Human
677	Parasitic Infections. Trends Parasitol. 2016 May;32(5):378–391.
678	59. Woith E, Fuhrmann G, Melzig MF. Extracellular Vesicles—Connecting Kingdoms. Int
679	J Mol Sci. 2019;20(22):5695.
680	60. Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et
681	al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a
682	position statement of the International Society for Extracellular Vesicles and update
683	of the MISEV2014 guidelines. J Extracell Vesicles. 2018 Dec 1;7(1):1535750.
684	61. Boukouris S, Mathivanan S. Exosomes in bodily fluids are a highly stable resource of
685	disease biomarkers. PROTEOMICS - Clin Appl. 2015 Apr;9(3-4):358-367.
686	62. Cappello F, Logozzi M, Campanella C, Bavisotto CC, Marcilla A, Properzi F, et al.
687	Exosome levels in human body fluids: A tumor marker by themselves? Eur J Pharm
688	Sci. 2017 Jan;96:93–98.
689	63. Taylor DD, Gercel-Taylor C. The origin, function, and diagnostic potential of RNA
690	within extracellular vesicles present in human biological fluids. Front Genet. 2013 Jul
691	30;4:142.
692	64. Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: Current knowledge
693	of their composition, biological functions, and diagnostic and therapeutic potentials.
694	Biochim Biophys Acta BBA - Gen Subj. 2012 Jul;1820(7):940–948.
695	65. Inamdar S, Nitiyanandan R, Rege K. Emerging applications of exosomes in cancer

therapeutics and diagnostics. Bioeng Transl Med. 2017 Mar;2(1):70–80.

- 697 66. Luo R, Liu M, Yang Q, Cheng H, Yang H, Li M, et al. Emerging Diagnostic Potential
- of Tumor-derived Exosomes. J Cancer. 2021;12(16):5035–5045.
- 699 67. Wang X, Tian L, Lu J, Ng IOL. Exosomes and cancer Diagnostic and prognostic
- biomarkers and therapeutic vehicle. Oncogenesis. 2022 Sep 15;11(1):54.
- 68. Cho SM, Shin S, Kim Y, Song W, Hong SG, Jeong SH, et al. A novel approach for
- tuberculosis diagnosis using exosomal DNA and droplet digital PCR. Clin Microbiol
- 703 Infect. 2020 Jul;26(7):942.e1-942.e5.
- 704 SUPPORTING INFORMATION CAPTIONS
- 705 Table S1. Patients information
- Table S2. Patients age ranges
- 707 Table S3. Distribution of origin in Bolivia in regions





121-122 Nested PCR





с

Consensus	8⊺	1 G	Т	A	GG	G	A	10	A	<mark>G G</mark>	G	TA	T	A	2() T	AC	Т	T (GC	T	3(A	A	G	ЗT	Т	TA	G	40	A	TT	A	G	гт	Т	50 G	I <mark>G</mark>	G	Т		A	П	6 G	0 Т	A		65 G	
Coverage	0							5.0														- 1/						_	10						_	0.2											407	
DO835656		44		X I				5,3						ν.	0.3						v i	. 1							sz .							92												
FWD seg8																		•																														
FWD seq1								_																		÷												÷										
FWD seq10				х.	• •		•		κ.	• •			•	2.3			• •			• •	2.1	• •		•	•				•		• •		•	• •										• •		• •	e e .	
FWD seq2		2.12	1.5	2.1			2	1.5	(2, 1)		\sim		12	4.1	1	\sim					2.1				1.2	\sim	a			1		1.5	e. 1				1.1			2.12		21	5.1		4	2.12	6 A.	
FWD seq6		• •	•	•	• •	•	• •	•	•	• •	•	• •	•	•	• •	•	• •	•	•	• •	•	• •	•	•	• •	•	• •	•	• •	•	• •	• •	•	• •	•	•	• •	•	•	• •	•	•	•	• •	•	• •	• •	
FWD seq3		• •	•		• •		• •	•	•	• •					• •		• •	•	•	• •		• •	•	•	• •	•	• •		• •	•	• •	• •	•	• •			• •			• •		•	•		•	•		
FWD seq11		1		1		÷	• •		1	• •	Ċ	1		1		1	• •	•	1	• •	1	• •		•	• •	1			1		• •	1	•	• •	1	•	11	Ċ		1	•		1			• •		
rwo sedy					• •					• •									•	• •		• •			• •								•	• •											•			







в



